Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL
1,649 views · Published 15 December 2017 · 8:54 · Indexed 31 October 2026
Channel: American Society of Hematology · 2017 · Nonprofits & Activism
Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma - a patient population with the "greatest unmet need."
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding